top of page
  • Writer's pictureJatin Agarwal

Innova Captab IPO

Innova Captab Logo

Innova Captab IPO: Stepping into the Pharmaceutical Spotlight

The Indian pharmaceutical industry is welcoming a new contender – Innova Captab Limited. Renowned for its diverse range of finished dosage formulations, Innova Captab plans to raise Rs 570 crore through an initial public offering (IPO) scheduled for December 21-26, 2023. This article delves into the details of the Innova Captab IPO, analyzing its potential and associated risks to aid informed investment decisions.

Company Overview:

Established in 1994, Innova Captab boasts a strong presence in the pharmaceutical market, offering over 850 formulations across various therapeutic segments. The company caters to both the domestic and export markets, partnering with leading pharmaceutical companies for contract manufacturing and development.

Financial Performance:

Innova Captab has demonstrated consistent revenue growth in recent years, climbing from Rs 286 crore in FY21 to Rs 389 crore in FY23, reflecting a healthy CAGR of 18.5%. The net profit also followed suit, increasing from Rs 30 crore in FY21 to Rs 42 crore in FY23. However, it's important to note that the profitability margin remains around 10.8%, slightly lower compared to some industry peers.

IPO Details:

  • IPO Opening Date: December 21, 2023.

  • IPO Closing Date: December 26, 2023.

  • Listing Date: December 29, 2023 (tentative).

  • Promoter Holding (Pre-IPO): 74.57%.

  • Promoter Holding (Post-IPO): 54.57%.

  • Lot Size: 33 Shares.

  • Price Band: Rs 426-448 per share.

Objectives of the Issue:

The funds raised through the IPO will be utilized for the following purposes:

  • Debt reduction: A significant portion of the proceeds will be allocated to pay off existing debt, bolstering the company's financial health and potentially reducing interest expenses.

  • Brand expansion: The company plans to utilize a substantial amount of the capital to accelerate store expansion and enhance brand visibility.

  • Working capital requirements: The remaining funds will cater to general corporate needs and day-to-day operations.

Potential and Risks:


  • Booming pharmaceutical market: The Indian pharmaceutical market is projected to reach Rs 71,000 crore by 2026, driven by factors like rising disposable income and an aging population. Innova Captab's diverse product portfolio and strong distribution network position it well to capitalize on this growth.

  • Contract manufacturing opportunities: The growing demand for contract manufacturing services from global pharmaceutical companies presents an attractive avenue for Innova Captab's expansion.

  • Government support: The Indian government's initiatives like "Make in India" and "Production Linked Incentive Scheme" (PLI) offer potential tailwinds for domestic pharmaceutical players like Innova Captab.


  • Competition: The Indian pharmaceutical market is highly competitive, with established players like Sun Pharma and Dr. Reddy's Laboratories. Innova Captab needs to maintain its cost competitiveness and product differentiation to stand out.

  • Dependence on third-party manufacturers: Some of Innova Captab's products are manufactured by third-party vendors, exposing them to quality control risks and potential supply chain disruptions.

  • Regulatory headwinds: The stringent regulatory environment in the pharmaceutical industry can lead to delays in product approvals and market entry, impacting the company's growth prospects.

Grey Market Premium (GMP):

As of December 18, 2023, the Innova Captab IPO has a Grey Market Premium (GMP) of Rs 8 per share. This indicates a neutral to mildly positive market sentiment, although GMP is not a guarantee of actual listing price or future performance.


The Innova Captab IPO presents both promising opportunities and potential pitfalls for investors. The thriving pharmaceutical market, diverse product portfolio, and government support offer intriguing growth prospects. However, the competitive landscape, dependence on third-party manufacturers, and regulatory headwinds warrant careful consideration. Investors should thoroughly analyze these factors, conduct their own research, and consult with financial advisors before making investment decisions in the Innova Captab IPO.

Disclaimer: All information is provided for educational and informational purposes only. Data is fetched from publicly available sources such as the DRHP filed by the company and other reliable sources. The website or the author takes no guarantee for the accuracy of the data; however, we have tried our best to present accurate data to our readers. Please consult a financial advisor or do your own analysis before investing/trading in the stock market.

544 views0 comments

Recent Posts

See All


bottom of page